VIR
Vir Biotechnology Inc

6,305
Mkt Cap
$859.89M
Volume
716,978.00
52W High
$14.45
52W Low
$4.16
PE Ratio
-1.54
VIR Fundamentals
Price
$6.45
Prev Close
$6.19
Open
$6.22
50D MA
$5.35
Beta
1.49
Avg. Volume
1.22M
EPS (Annual)
-$3.83
P/B
0.91
Rev/Employee
$181,875.00
Loading...
Loading...
News
all
press releases
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2025, on November 5...
Business Wire·6d ago
News Placeholder
More News
News Placeholder
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in Part 3 of the Companys Phase 1 clinical trial evaluating VIR-5500 in combination with androgen receptor...
Business Wire·19d ago
News Placeholder
Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains?
Vir Biotechnology (VIR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·19d ago
News Placeholder
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -11.11% and -84.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise
GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.
Zacks·3mo ago
News Placeholder
Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Vir Biotechnology (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago
News Placeholder
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?
Vir Biotechnology (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·4mo ago
News Placeholder
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the executive team are scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday...
Business Wire·8mo ago
News Placeholder
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2024, on...
Business Wire·9mo ago
News Placeholder
Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20
investing.com·10mo ago

Latest VIR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.